Orexigen Therapeutics Inc

Orexigen Therapeutics — Investor Presentation (January 2014)

43 slides from Orexigen Therapeutics's investor presentation, Jan 13, 2014

  1. Slide 1: January 2014

    January 2014 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements about Orexigen Therapeutics, Inc. and its lead product candidate, NB 32. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "desig

  3. Slide 3: Obesity is a Growing Global Epidemic

    2000 2000 Africa (AFR) SE Asia (SEA) 2000 2020 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 303m Obesity is a Growing Global Epidemic 86m North America and Caribbean (NAC) South and Central America (SACA) Western Pacific (WP) Europe (EUR) Middle East and North Africa (MENA) millions of people 9

  4. Slide 4: Obesity is a Growing Global Epidemic

    2010 2000 2000 2010 Africa (AFR) SE Asia (SEA) 2000 2020 2000 2010 2000 2000 2010 2000 2000 2010 2000 2010 2000 2000 2010 2000 2000 2010 472m 303m Obesity is a Growing Global Epidemic 86m 110m North America and Caribbean (NAC) South and Central America (SACA) Western Pacific (WP) Europe (EUR) Middle

  5. Slide 5: Obesity is a Growing Global Epidemic

    2010 2000 2020 2000 2010 2020 Africa (AFR) SE Asia (SEA) 2000 2020 2000 2010 2020 2000 2000 2010 2020 2000 2000 2010 2020 2000 2000 2010 2000 2000 2010 2020 2000 2000 2010 2020 472m 303m Obesity is a Growing Global Epidemic 672m 86m 110m 149m North America and Caribbean (NAC) South and Central Ameri

  6. Slide 6: Obesity and Co-Morbid Diabetes Increase Risk of Coronary Heart Disease

    Annual Cost in US: $ 245B Diabetes Cardiovascular Disease (CVD): $ 444B Excess Weight and the Risk of Coronary Heart Disease Among Men Obesity and Co-Morbid Diabetes Increase Risk of Coronary Heart Disease Source: Obesity: Volume 18, Issue 2, pages 377-383, 6 SEP 2012 DOI: 10.1038/oby.2009.223 http:

  7. Slide 7: Weight Loss Improves Cardiometabolic Risk Factors

    Therapeutic Class Cardiometabolic Risk Factors Adversely Impacted by Excess Weight US 2011 Total Rx Expenditures (billions) Global 2011 Total Rx Expenditures (billions) * Insulin excluded Weight Loss Improves Cardiometabolic Risk Factors Anti-hypertension Blood Pressure $14.2 $51.3 Anti-diabetes age

  8. Slide 8: How Will Obesity Therapeutics Become a Blockbuster Category?

    How Will Obesity Therapeutics Become a Blockbuster Category? Global approvals A clear safety profile established by positive outcomes trial data Large, skilled primary care marketing efforts Increased access and coverage for therapeutics and programs Continued investment in outcomes data establishin

  9. Slide 9: NB32 - Our Lead Investigational Medicine

    -7.1% NB32: A fixed dose combination of two drugs that demonstrates an unexpected and significant impact on weight loss Bupropion: Indications for depression, smoking cessation Naltrexone: Indications in anti-addiction NB32 - Our Lead Investigational Medicine naltrexone sustained release (SR)/buprop

  10. Slide 10: NB32: Issued Patents and Pending Applications

    Light Study (methods) Binge Eating (methods) Major Depression (methods) Visceral Fat (methods) Titration / Dose Pack (methods & devices) Trilayer (methods & compositions) Nal SR (methods & compositions) Food Cravings / Titration (methods) Insulin Sensitivity (methods & compositions) Weber / Cowley (

  11. Slide 11: NB32 Studies Have Included More Than 13,000 Patients

    Phase 2 & 3 clinical trials in 4,500+ patients established efficacy and safety profile Light Study CVOT evaluating NB32 vs. placebo in ~8,900 overweight and obese patients NB32 Studies Have Included More Than 13,000 Patients Phase 3 trials met co-primary and key secondary endpoints Reduction in body

  12. Slide 12: Our Focus is on Responders to Therapy

    Illustrative : Typical distribution of weight loss response to obesity therapy Our Focus is on Responders to Therapy Our Focus: Responders Non-responders discontinue drug therapy

  13. Slide 13: NB32 Responders Achieved Significant Weight Loss

    5 - <10 % -16 lbs 10 - <15 % -27 lbs 15 % -43 lbs 0 – <5 % -6 lbs COR-I and COR-II Responders NB32 Responders Achieved Significant Weight Loss Represents one year data for responders (patients with 5% weight loss at week 16)

  14. Slide 14: Combining NB32 with Behavioral Modification Drives Better Results

    COR-I and COR-II Responders COR-BMOD Responders -43 lbs -6 lbs -16 lbs 5 - <10 % 10 - <15 % -27 lbs 15 % -7 lbs -18 lbs 5 - <10 % 10 - <15 % -27 lbs -45 lbs 15 % 0 – <5 % 0 – <5 % Combining NB32 with Behavioral Modification Drives Better Results In COR-BMOD, 47% of responders completing one year of

  15. Slide 15: NB32 Well Established Safety Profile

    NB32 Well Established Safety Profile Safety profile consistent with bupropion and naltrexone labels Well tolerated in Phase 3 trials Most common AEs: – Mild to moderate and transient nausea during dose escalation – Low frequency reports of dry mouth, headache, dizziness, insomnia Phase 3 SAEs infreq

  16. Slide 16: The Light Study Will Supplement the NB32 Profile with CV Outcomes Data

    NB32 + WeightMate™ The Light Study Will Supplement the NB32 Profile with Cardiovascular Outcomes Data Light Study Randomized Approximately 8,900 Patients With History of CV Disease or Diabetes + CV Risk Factors Primary endpoint is ITT analysis of MACE (MI, stroke, CV death) Real-world test - long te

  17. Slide 17: Light Study Interim Analysis Met Goal Set by FDA

    Category Criteria Result Light Study Interim Analysis Met Goal Set by FDA and Clearly Satisfied CRL CV Outcomes Interim Analysis to Rule out excess cardiovascular risk (H/R < 2.0, 95% CI) Overall Safety No new safety signals observed

  18. Slide 18: Orexigen is Confident Light Study Interim Results Support Favorable Benefit:Risk

    Orexigen is Confident Light Study Interim Results Support a Favorable Benefit : Risk Assessment Time to first occurrence of MACE, the primary endpoint Time to first occurrence of the three components of MACE: non fatal heart attack, non fatal stroke, and cardiovascular death Death from any cause Uns

  19. Slide 19: Light Study Data are Generalizable to the Broader Obese Population

    Characteristics Mean All* (N=8905) Source: Table 4,5, and 6, DMC Summary Report of Light Study interim analysis * Numbers are rounded Average age (years) Gender (M/F) 45.5 / 54.5% Race White Other races/not reported BMI (kg/m ) Current Tobacco Smoker History of Depression Use of SSRI Use of other an

  20. Slide 20: Confident in Prospects for US and EU Approvals in 2014

    Q4 2013 Q1 2014 Q2 2014 Q3 2014 NDA Resubmission: FDA Review Orexigen Confident in Prospects for US and EU Approvals in 2014 Filings contain an unprecedented amount of pre-approval cardiovascular outcomes information for an obesity therapeutic June 10, 2014 PDUFA date Anticipated European approval y

  21. Slide 21: NB32 Poised for Commercial Success

    Skilled partner with heavy resourcing Differentiated product profile Unmet need / limited competition Large, growing market NB32 Poised for Commercial Success > > > >

  22. Slide 22: Robust Market Research Shows NB32 Preferred for Important Patient Groups

    Robust Market Research Shows NB32 Preferred for Important Patient Groups NB32 had high preference share and/or willingness to prescribe among – Women – Obese patients with depression – Obese patients with diabetes – Obese patients reporting issues with food cravings and eating control Market researc

  23. Slide 23: Majority of Obesity Prescriptions go to Women

    Majority of Obesity Prescriptions go to Women Age (years) Source: Orexigen market research; IMS Health, National Disease and Therapeutic Index 1,000 1,500 2,000 2,500 3,000 0-19 20-39 40-59 60-64 65+ Female Male

  24. Slide 24: Preference Share Separated in Favor of NB32 for Women

    Product preference for male vs. female patients Preference Share Separated in Favor of NB32 for Women NB32 Qsymia Belviq Source: Orexigen quantitative research, 2012 MALE FEMALE % % % Sex 39.9% 28.1% 32.0% 32.5% 34.8% 32.7%

  25. Slide 25: Obese Population Often has Co-morbid Depression

    Antidepressants in Obese Population Obese Population Often has Co-morbid Depression or is on Antidepressants Physicians report that approximately 1/3 of obese patients are diagnosed and/or treated for depression Another 1/3 of obese patients display signs and symptoms of untreated depression The pro

  26. Slide 26: High Willingness To Prescribe NB32 for Obese Patients With Depression

    Willingness to prescribe NB32 Willingness to prescribe NB32 YES 92% YES 72% High Willingness To Prescribe NB32 for Obese Patients With Co-morbid Depression Utilization intent measures indicate 92% of physicians would be willing to prescribe NB32 to obese patients who: – Display depressive symptoms b

  27. Slide 27: Obesity Viewed as a Driver of Diabetes

    41 % Obesity Viewed as a Driver of Diabetes Obesity is increasing globally - a key factor driving diabetes rates Rates of obesity have risen dramatically worldwide and in the United States over the past several decades Diabetes costs in the US are $245 billion annually up 41% from 2007 to 2012 79 m

  28. Slide 28: New Market Research Suggests Strong Physician Interest in NB32

    New Market Research Suggests Strong Physician Interest in NB32 For Obese Patients with Co-morbid Diabetes or Prediabetes 500 physicians - 200 Primary Care physicians - 200 OB/GYN physicians - 100 Endocrinologists Both users and non-users of anti-obesity agents were surveyed Profile derived from the

  29. Slide 29: Nearly 60% of all Obese Patients have Diabetes or Prediabetes

    US Obesity Distribution - 2010 33.1m 35.7m 9.4m Obese With Diabetes Obese with Prediabetes Obese Without Diabetes or Prediabetes Nearly 60% of all Obese Patients have Diabetes or Prediabetes Source: National Diabetes Fact Sheet, 2011; 2010 National Health and Nutrition Survey Total Obese Patients =

  30. Slide 30: Use of Obesity Therapeutics in These Groups Expected to Increase

    Treatment of Obese Patients with Diabetes Treatment of Obese Patients with Prediabetes Use of Obesity Therapeutics in These Groups Expected to Increase Significantly in Next Five Years Future Patients Current Patients Future Patients Current Patients 4X Increase 4.6X Increase Source: Orexigen NB32 M

  31. Slide 31: Strong Interest in Prescribing NB32 in Patients with Diabetes or Prediabetes

    9.4m US Obese Patients With Diabetes 71% 39% 77% 41% 35.7m US Obese Patients With Prediabetes Strong Interest in Prescribing NB32 for Obesity in Patients with Diabetes or Prediabetes % Physicians Interested in Prescribing % of Patients Likely to be Prescribed NB32 % Physicians Interested in Prescrib

  32. Slide 32: Key Factors Influencing Physicians to Prescribe NB32

    Key Factors Influencing Physicians to Prescribe NB32 for Obesity in Patients with Diabetes or Prediabetes Overall Product Profile Impacts Likelihood to Prescribe Efficacy: High proportion of patients losing 5% or 10% body weight Combining treatment with behavioral modification dramatically increased

  33. Slide 33: Faster Adoption Expected in Obese Patients with Diabetes or Prediabetes

    NB32 Estimated Adoption by Patient Type Faster Adoption Expected in Obese Patients with Diabetes or Prediabetes Experimental Basis Use as soon as approved After most of my colleagues have tried Use after a few colleagues have tried All patients Obese patients with diabetes or prediabetes* 0% 100% So

  34. Slide 34: NB32 Potential Lifecycle Opportunities

    NB32 Potential Lifecycle Opportunities Diabetes-Obesity Fixed Dose Combination: Completed formulation work for human bioequivalence studies (NB32 + DPP4) Potential for diabetes indication – In COR-Diabetes, NB32 demonstrated placebo corrected A1C reductions of as much a 0.7%* – Single additional 26

  35. Slide 35: Strong Partnership with Takeda

    Strong Partnership with Takeda $50M upfront payment 20 – 35% tiered royalty on net sales $1 billion potential milestones, including $100M between approval and launch Takeda covers all commercialization costs Takeda shares in post approval clinical development costs Orexigen retains a right to co-pro

  36. Slide 36: Takeda Commercial Expertise and Resources Across All Commercial Functions

    Integrated Launch Execution Channel Fill Strategy Professional Strategy Sales Strategy Managed Market Strategy Patient Strategy Takeda Commercial Expertise and Resources Across All Commercial Functions

  37. Slide 37: Targeting Optimal Physician Audiences with Skill and Scale

    Targeting Optimal Physician Audiences with Skill and Scale for Successful Launch Takeda has 2,000+ field personnel in the US Assuming approval, an appropriate number of them will detail NB32 to provide the reach and frequency required to effectively launch a product in primary care Takeda’s size and

  38. Slide 38: Access and Coverage are Increasing

    From Q3 2012 – Q2 2013, ~40% of branded obesity therapeutics claims were covered for patients with commercial insurance Medicare now covers obesity counseling; legislation introduced to cover obesity therapeutics Public policy pressure and legislative efforts are increasing to address the obesity ep

  39. Slide 39: EU and ROW Opportunity for Obesity Therapeutics is Large

    Historic Worldwide Anti-Obesity Sales in 2007 US 19% Europe 35% ROW 46% EU and ROW Opportunity for Obesity Therapeutics is Large Historic Anti-Obesity Sales in 2007 ~ $1.7 billion Source: IMS

  40. Slide 40: Rates of Obesity Have Risen Dramatically in Several Key Regions

    2010 2020 2010 2020 2010 2020 AUS $53.5 2010 2020 Rates of Obesity Have Risen Dramatically in Several Key Regions Over the Past Several Decades Source: EuroMonitor, 2010; WHO Statistics All sales are from2007 in $ USD (Millions) millions of people BRAZIL $130.4 28.2m 26.9m 6.4m 4.8m 42.0m 25.4m $48.

  41. Slide 41: Orexigen Financial Position is Strong

    Orexigen Financial Position is Strong Revenue drivers $100M in milestones to Orexigen between approval and first commercial sale Tiered royalties of 20-35% on net sales in North America Potential sales milestones up to $880M Proceeds from potential ROW partnership Expenses Corporate: Orexigen runs l

  42. Slide 42: Potential Key Catalysts for 2014

    Potential Key Catalysts for 2014 Near Term Catalysts and Financial Strength Position Orexigen for Transformational Year ROW partnership progress EU approval US launch US approval

  43. Slide 43: Orexigen

    is OREXIGEN

Orexigen Therapeutics — Investor Presentation (January 2014) on 6ix